News
Your source for the latest updates, breakthroughs, and insights in drug development and manufacturing. Explore our featured stories, press releases, and event announcements to stay informed about our innovations and contributions to drug development and manufacturing advancements.
Shortening FDA-Mandated CAR T-Cell Therapy Monitoring Periods Could Improve Access to Treatment in Patients With DLBCL
Two hallmark toxicities of chimeric antigen receptor (CAR) T-cell therapy may be rare after 2 weeks following infusion in patients with diffuse large B-cell lymphoma (DLBCL), supporting a shorter, more flexible toxicity monitoring period, according to a recent study...
Avance Biosciences Launches Newly Redesigned Website
Avance Biosciences is excited to announce the launch of our newly redesigned website, aimed at enhancing user experience and providing comprehensive information about our cutting-edge biotechnology services.
American Assoc. of Pharmaceutical Scientists (AAPS) National Biotechnology Conference – 2024
Avance Biosciences™ offers top-tier GLP & GMP compliant services in assay development, validation, & sample testing for biopharma. Visit our booth to explore how we support drug discovery, development, & manufacturing with precision & expertise. [...]
American Society of Gene and Cell Therapy (ASGCT) Conference – 2024
Avance Biosciences™ is excited to announce our participation in the American Society of Gene & Cell Therapy (ASGCT) conference, where we’ll be showcasing our advanced services and expertise to propel the future of gene and cell therapy. [...]
Workshops on Recent Issues in Bioanalysis (WRIB) Conference – 2024
Ensure the Success of Your Biological Drug Development - Avance Provides Assays to Support your Biopharmaceutical Development & Manufacturing - Avance Biosciences™ is a world-leading CRO specializing in GLP & GMP compliant biological assay development, assay validation, and [...]
Stealing Strategies from Cancerous T Cells May Boost Immunotherapy
CAR T-cell therapies show promise for blood cancers but struggle with solid tumors due to T-cell weakness in tumor microenvironments. Researchers find genetic alterations in cancerous T cells, giving engineered T cells "superpowers" to effectively kill tumors without behaving like cancer cells...